Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial

Core Insights - Eli Lilly's Zepbound demonstrated superior weight loss results compared to Novo Nordisk's Wegovy in a recent clinical study, with Zepbound patients losing an average of 20.2% of their body weight versus 13.7% for Wegovy patients [2][4] - The average weight loss translates to approximately 50 pounds for Zepbound users compared to about 33 pounds for those on Wegovy [3] - The study involved 751 patients over a 72-week trial period, reinforcing the efficacy of Zepbound in weight management [2] Company Performance - Both Eli Lilly and Novo Nordisk have seen fluctuations in their stock prices, but they remain positive for the year, with Eli Lilly shares up 43% and Novo Nordisk up 6% since the beginning of 2024 [6] - The recent clinical study results have positively impacted Eli Lilly's stock, which rose more than 3% following the announcement, while Novo Nordisk's U.S.-listed shares increased by about 0.8% [6] - The popularity of weight-loss drugs has significantly boosted sales for both companies, especially after the Biden administration proposed covering these medications through Medicare and Medicaid [5]